[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
From the Centers for Disease Control and Prevention
September 15, 1999

Selman Abraham Waksman, PhD

JAMA. 1999;282(11):1030. doi:10.1001/jama.282.11.1030-JWR0915-2-1

In 1943, Selman Abraham Waksman (July 22, 1888-August 16, 1973) led a team of Rutgers University researchers that isolated streptomycin, the first antibiotic effective against tuberculosis (TB) in humans. In 1952, Waksman received the Nobel Prize for this discovery.

Waksman grew up in the small Russian village of Novaya Priluka. In 1910, he settled in New Jersey, where a cousin operated a small farm. An interest in scientific farming brought him to nearby Rutgers College of Agriculture, where he earned a bachelor's degree in science in 1915 and a master's degree a year later. He completed his doctorate at the University of California, Berkeley, in 2 years, and returned to Rutgers to take a position as lecturer in soil microbiology.

Waksman preferred the term "microbiology" to the conventional "bacteriology" because "not the bacteria but the fungi and the actinomycetes formed my major interests among the microorganisms."1 By the 1930s, he was a leading figure in microbiology, attracting talented graduate students, including Rene Dubos, whose work led to the discovery in 1939 of gramicidin, the first clinically useful topical antibiotic.

Dubos' success and the introduction of penicillin prompted Waksman to put his graduate students and assistants to work looking for antibiotics. In 1943, a Waksman student, Albert Schatz, isolated streptomycin. In 1944, clinical trials demonstrated the drug's effectiveness against gram-negative bacteria including Mycobacterium tuberculosis. Despite substantial problems with toxicity and drug resistance, streptomycin soon formed the foundation of multidrug therapies for TB.

With the introduction and use of antibiotics, mortality of TB was reduced drastically. In the United States, from 1945 to 1955, TB mortality decreased from 39.9 deaths per 100,000 population2 to 9.1. Around the world, TB remained (and remains) a substantial health problem, but until the emergence of multidrug-resistant TB, many in the United States shared Waksman's optimism, expressed in 1964, that "the final chapter of the battle against tuberculosis appears to be at hand."3

Back to top
Article Information
Dowling HF. Fighting infection: conquests of the twentieth century. Cambridge, Massachusetts: Harvard University Press, 1977.
Levy SB. The antibiotic paradox: how miracle drugs are destroying the miracle. New York, New York: Plenum Press, 1992.
Ryan F. The forgotten plague: how the battle against tuberculosis was won—and lost. Boston, Massachusetts: Little, Brown, 1993.
References
1.
Waksman  S My life with the microbes.  New York, New York Simon and Schuster1954;100
2.
Groves  RDHetzel  AM Vital statistics rates in the United States, 1940-1960.  Washington, DC National Center for Health Statistics1968;(PHS publication no. 1677).
3.
Waksman  S The conquest of tuberculosis.  Berkeley, California University of California Press1964;193
×